Everolimus
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.
🧴 Clinical Application
Oncology: Take orally 10 mg once daily with water, consistently with or without food. Transplant: Take 0.75 mg twice daily with therapeutic drug monitoring. Swallow tablets whole; do NOT chew or crush. Prophylactic alcohol-free dexamethasone mouthwash is recommended to prevent stomatitis.
⚠️ Side Effects
Common: Aphthous stomatitis / mouth ulceration (occurs in >60%), rash, fatigue, diarrhea, hyperglycemia, hyperlipidemia, infections, anemia. Rare/Severe: Non-infectious pneumonitis / interstitial lung disease, severe infections, and acute renal failure.
🛡️ Safety Warnings
Non-infectious pneumonitis is a class effect; monitor for cough or dyspnea and interrupt therapy if grade 2+ pneumonitis occurs. High incidence of stomatitis; manage with steroid mouthwashes. Monitor fasting blood glucose and lipid panel routinely. Substrate of CYP3A4.
Jan Aushadhi Products containing Everolimus
Found 4 generic formulation(s) containing this active ingredient.
Everolimus Tablets 0.25 mg
Everolimus Tablets (0.25mg, 0.5mg, 5mg, 10mg) is an oral derivative of rapamycin that selectively inhibits the mTORC1 serine/threonine kinase complex on the WHO Model List of Essential Medicines. In oncology, mTOR inhibition halts downstream protein synthesis (p70S6K, 4E-BP1), blocking cell proliferation, nutrient sensing, and VEGF-driven angiogenesis. In organ transplantation, it suppresses lymphocyte activation. Indicated for HR+/HER2- advanced breast cancer (with exemestane), advanced renal cell carcinoma, pancreatic/gastrointestinal/lung neuroendocrine tumors (NET), subependymal giant cell astrocytoma (SEGA), and renal angiomyolipoma with tuberous sclerosis; lower doses (0.25/0.5mg) are used for kidney and liver transplant rejection prophylaxis.
Everolimus Tablets 0.5 mg
Everolimus Tablets (0.25mg, 0.5mg, 5mg, 10mg) is an oral derivative of rapamycin that selectively inhibits the mTORC1 serine/threonine kinase complex on the WHO Model List of Essential Medicines. In oncology, mTOR inhibition halts downstream protein synthesis (p70S6K, 4E-BP1), blocking cell proliferation, nutrient sensing, and VEGF-driven angiogenesis. In organ transplantation, it suppresses lymphocyte activation. Indicated for HR+/HER2- advanced breast cancer (with exemestane), advanced renal cell carcinoma, pancreatic/gastrointestinal/lung neuroendocrine tumors (NET), subependymal giant cell astrocytoma (SEGA), and renal angiomyolipoma with tuberous sclerosis; lower doses (0.25/0.5mg) are used for kidney and liver transplant rejection prophylaxis.
Everolimus Tablets 5 mg
Everolimus Tablets (0.25mg, 0.5mg, 5mg, 10mg) is an oral derivative of rapamycin that selectively inhibits the mTORC1 serine/threonine kinase complex on the WHO Model List of Essential Medicines. In oncology, mTOR inhibition halts downstream protein synthesis (p70S6K, 4E-BP1), blocking cell proliferation, nutrient sensing, and VEGF-driven angiogenesis. In organ transplantation, it suppresses lymphocyte activation. Indicated for HR+/HER2- advanced breast cancer (with exemestane), advanced renal cell carcinoma, pancreatic/gastrointestinal/lung neuroendocrine tumors (NET), subependymal giant cell astrocytoma (SEGA), and renal angiomyolipoma with tuberous sclerosis; lower doses (0.25/0.5mg) are used for kidney and liver transplant rejection prophylaxis.
Everolimus Tablets 10 mg
Everolimus Tablets (0.25mg, 0.5mg, 5mg, 10mg) is an oral derivative of rapamycin that selectively inhibits the mTORC1 serine/threonine kinase complex on the WHO Model List of Essential Medicines. In oncology, mTOR inhibition halts downstream protein synthesis (p70S6K, 4E-BP1), blocking cell proliferation, nutrient sensing, and VEGF-driven angiogenesis. In organ transplantation, it suppresses lymphocyte activation. Indicated for HR+/HER2- advanced breast cancer (with exemestane), advanced renal cell carcinoma, pancreatic/gastrointestinal/lung neuroendocrine tumors (NET), subependymal giant cell astrocytoma (SEGA), and renal angiomyolipoma with tuberous sclerosis; lower doses (0.25/0.5mg) are used for kidney and liver transplant rejection prophylaxis.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Everolimus.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Everolimus Tablets 0.25 mg | 10's | ₹250.00 | EVERGRAF, EVEROGRESS | ₹595.24 | 58% Save |
| Everolimus Tablets 0.5 mg | 10's | ₹450.00 | EVERGRAF, CERTICAN, EVEROGRESS | ₹1491.26 | 70% Save |
| Everolimus Tablets 5 mg | 10's | ₹3600.00 | BOLETRAAZ | ₹17820.00 | 80% Save |
| Everolimus Tablets 10 mg | 10's | ₹7000.00 | EVERMIL | ₹6526.40 | N/A |
Frequently Asked Questions (FAQ)
Get answers to common queries about Everolimus generics.